Phase II Study of VELCADE for Relapsed or Refractory T-cell Prolymphocytic Leukemia

Summary

We hope to learn more about the clinical efficacy of bortezomib in T-cell prolymphocytic leukemia. Patients will be selected as a possible participant in this study because they have a bone marrow disorder known as T-cell prolymphocytic leukemia (T-cell PLL) which does not tend to respond well to conventional treatment with chemotherapy.

Timeline

Start

2010-06

Primary completion

2011-07

Completion

2011-07

Outcome

Outcome not reported

Stopped (Enrollment): “no accrual”

Drugs

Indications